The safety of treatments for tobacco use disorder

  title={The safety of treatments for tobacco use disorder},
  author={Melissa A Little and Jon O. Ebbert},
  journal={Expert Opinion on Drug Safety},
  pages={333 - 341}
ABSTRACT Introduction: Tobacco continues to be a leading cause of preventable morbidity and mortality in the world. First-line pharmacotherapies for the treatment of tobacco use disorder include nicotine replacement therapy, bupropion sustained-release (SR), and varenicline. We provide an overview of current evidence on the safety of first-line pharmacotherapies for the treatment of tobacco use disorder. Areas covered: Randomized clinical trials published in English up to July 2015 were… 

A systematic review of possible serious adverse health effects of nicotine replacement therapy

Limited evidence indicated a lack of effect between NRT exposure and SAHEs for CVD and various reproduction/developmental endpoints and the evidence was inadequate to demonstrate any association with NRT use.

Poor Practitioner Adherence to Clinical Tobacco Use Guidelines in Liver Transplant Recipients

Although tobacco use cessation counseling and interventions were not associated with a decrease in CVEs, evidence-based interventions for tobacco use were under utilized in this high cardiac risk population, which underscore missed opportunities for transplant practitioners to provide tobaccoUse cessation interventions to LTRs, which could reduce CVEs.

Evaluation of the neuropathic pain in the smokers.

  • Sercan ÇelikH. Can O. Aygün
  • Medicine
    Agri : Agri (Algoloji) Dernegi'nin Yayin organidir = The journal of the Turkish Society of Algology
  • 2017
The possibility of neuropathic pain increases as the duration of smoking and addiction level increase, and with diabetes, this rate increases even more; it is extremely important that the smokers should be informed regarding these facts and possibilities.

Addictive behaviors in liver transplant recipients: The real problem?

This review describes data about alcohol and illicit drug use by transplant recipients and suggests guidelines for behavior management after surgery, and suggests an addiction specialist in a LT team seems to be very important.

Step Care treatment for smoking cessation

No statistically significant difference was observed in prolonged smoking abstinence between the Step Care and Recycle condition, and additional research is needed to explore whether a stepped care intervention increases long-term smoking abstinence rates compared with repeating the same intervention.

Ausgestaltung und Barrieren für eine Tabakentwöhnung in Hausarztpraxen: Ergebnisse einer qualitativen Studie

Ziel der Studie Etwa 25% der deutschen Bevölkerung raucht. Obgleich Tabakentwöhnung eines der effektivsten Mittel zur Reduktion tabakassoziierter Folgen ist, findet sie nicht ihren Weg in die

Release Kinetics of Nicotine Loaded onto Mesoporous Silicate Materials for Use in Nicotine Replacement Therapy.

In this work, loading of nicotine onto mesoporous silicate materials and its release into a phosphate buffer solution at 37°C were investigated and a slight increase in loading capacity with increasing pore size was observed.



Adverse Effects and Tolerability of Medications for the Treatment of Tobacco Use and Dependence

The benefit: risk ratio is strongly in favour of pharmacotherapy for tobacco dependence treatment in virtually all smokers who are motivated to quit, and the risks of continued tobacco use and the benefits of treatment are strong.

Emerging drugs for the treatment of tobacco dependence: 2014 update

Current evidence suggests that the two most effective pharmacotherapies to treat tobacco dependence are varenicline and combination nicotine replacement therapy, both of which demonstrate mixed rates of success in achieving long-term abstinence from smoking.

Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

The outcome for benefit is continuous or prolonged abstinence at least six months from the start of treatment, and the outcome for harms is the incidence of serious adverse events associated with each of the treatments.

Bupropion sustained release for treatment of tobacco dependence.

The clinical characteristics of patients at higher risk for adverse effects when bupropion SR is prescribed for treatment of tobacco use and dependence are delineated and the risk of serious adverse effects associated with buPropion SR can be reduced by careful selection of patients.

Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis.

The limited evidence available to date suggests that bupropion and varenicline are effective and tolerable for smoking cessation in adults with serious mental illnesses.

Antidepressants for smoking cessation.

Some antidepressants (bupropion and nortriptyline) can aid smoking cessation, but it is not clear whether these effects are specific for individual drugs, or a class effect.

Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study.

Varenicline shows efficacy for initiating smoking cessation in bipolar patients, but medication trials of longer duration are warranted for maintaining abstinence.

Nicotine replacement therapy in smoking cessation.

Evidence for benefit from nicotine replacement therapy in hospital patients is inconclusive, although the results of a trial reported in this issue of Thorax give cause for optimism and should

Interventions for smoking cessation and reduction in individuals with schizophrenia.

Contingent reinforcement (CR) with money may increase smoking abstinence rates and reduce the level of smoking in patients with schizophrenia, however, it is uncertain whether these benefits are maintained in the longer term.

Tobacco dependence and the nicotine patch. Clinical guidelines for effective use.

Nicotine patches are an effective aid to tobacco dependence treatment, however, success rates vary greatly across research studies and may be influenced highly by the nature and intensity of adjuvant smoking cessation counseling.